Patrick J. Heron - 06 Mar 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Steve R. Bailey, Attorney-in-Fact For Patrick J. Heron
Issuer symbol
MIRM
Transactions as of
06 Mar 2025
Net transactions value
+$83,661
Form type
4
Filing time
10 Mar 2025, 17:12:58 UTC
Previous filing
06 Mar 2025
Next filing
12 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Purchase $58,597 +1,335 +0.81% $43.89 165,245 06 Mar 2025 By Frazier Life Sciences X, L.P. F1, F2
transaction MIRM Common Stock Purchase $25,064 +580 +0.35% $43.21 165,825 07 Mar 2025 By Frazier Life Sciences X, L.P. F2, F3
holding MIRM Common Stock 3,566,912 06 Mar 2025 By Frazier Life Sciences IX, L.P. F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.42 to $44.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
F2 The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.79 to $43.42, inclusive.
F4 The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.